AstraZeneca recently completed a major acquisition deal with French MedTech Amolyt Pharma. This clinical-stage biotechnology company specializes in finding innovative treatments for rare endocrine diseases. The acquisition will expand AstraZeneca’s rare disease late-stage pipeline and strengthen its bone metabolism franchise. As part of the agreement, AstraZeneca acquired all of Amolyt Pharma’s outstanding shares for a total of up to $1.05bn, which includes an upfront payment of $800 million and a contingent payment of $250m for meeting a pre-specified regulatory milestone.
This acquisition could significantly benefit patients with hypoparathyroidism, a deficiency in parathyroid hormone (PTH) production that results in abnormal calcium and phosphate regulation, which can lead to debilitating symptoms and complications such as chronic kidney disease.
At AstraZeneca, we are committed to acquiring and investing in companies that align with our vision of providing innovative medical solutions that positively impact people’s lives.
In other news, our commitment to innovation has also led us to back the enzyme trailblazer Entropix, along with LYVA Labs. We are always on the lookout for opportunities to support groundbreaking companies that have the potential to improve healthcare outcomes for patients.
As we continue to forge ahead with impactful innovations and collaborations, our goal remains the same: to provide high-quality, life-changing medical solutions that have the power to transform healthcare around the world.
